Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Iveric Bio’s AMD Drug Approved in US, Launch Set for This Month: Astellas
August 8, 2023
- Global PIII Study for Zipalertinib Begins for 1st Line NSCLC: Taiho
August 8, 2023
- Nippon Shinyaku’s DMD Therapy Gets Orphan Tag in US
August 8, 2023
- Kyowa Kirin Chief Admits Difficulties in Trial Design Felt with Dumped Kidney Disease Med
August 7, 2023
- Wakamoto Seeks to Add New Manufacturer for MaQaid amid Supply Woes
August 7, 2023
- Mitsubishi Tanabe Aims to Maximize Value of Mounjaro through Synergies with Other Products
August 4, 2023
- Kyowa Kirin’s 6-Month Sales Up 7.5% as Global Brands Log Positive Growth
August 4, 2023
- Rakuten Medical Gears Up for Global Pitch on Photoimmunotherapy: Chairman
August 4, 2023
- Lonsurf-Bevacizumab Snags US Approval for Colorectal Cancer: Taiho
August 4, 2023
- Opdivo Tops Japan Sales Ranking for 19 Months on End: Encise
August 4, 2023
- Eisai Sees Positive Shift in US Market for Leqembi after Full Approval: Exec
August 3, 2023
- Sumitomo to Focus on 3 Core Products in North America to Overcome Latuda Patent Cliff: President
August 3, 2023
- Mitsubishi Tanabe’s Q1 Sales Up 3.8% on Back of Bullish Oral Radicava Sales in US
August 3, 2023
- Pfizer’s Bivalent COVID Vaccines Approved for Primary Series in Japan
August 3, 2023
- Eligibility Age of Moderna COVID Vaccine Lowered to 6 and Older
August 3, 2023
- Moderna Japan’s XBB-Based COVID Jab Actually Filed for Age 6 and Up
August 3, 2023
- Japan OKs 1st Homemade COVID Jab, but No Supply Planned; Daiichi to Pursue XBB.1 Update
August 3, 2023
- Eisai’s Q1 Operating Profit Jumps on Lenvima Growth, Lower Aduhelm Cost
August 3, 2023
- Japan Greenlights Shionogi’s Stable Supply Plan for 2 Cephalosporin Antibiotics
August 2, 2023
- Mitsubishi Tanabe Drops Once-Daily Oral Edaravone Regimen for ALS
August 2, 2023
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…